Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients without insurance.

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This includes Wegovy (the weight-loss dose of Ozempic, or semaglutide) and Mounjaro ...

Novo Nordisk ... Ozempic is indicated as as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D), to reduce the risk of major adverse cardiovascular (CV) ...